Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Randomized Controlled Trial

Research Support, Non-U.S. Gov't

Comparative Study

Observational Study

Multicenter Study

Clinical Trial, Phase III

Research Support, N.I.H., Extramural

Letter

Review

Case Reports

Clinical Trial, Phase IV

Clinical Trial

Publication Year

From

Quick links

Individual year

2022

2021

2020

2019

2018

2016

2014

2013

2012

2011

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for

""Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination""[mesh_terms]

15 Results

Searching titles within these results

Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review.

Merry Huang, Richard A Prayson, Yuebing Li

Journal of clinical neuromuscular disease 2022;24(2):75-79

Full Text

Abstract

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Jose I Bernardino, Amanda Mocroft, Cedrick Wallet, Stéphane de Wit, Christine Katlama, Peter Reiss, Patrick W Mallon, Laura Richert, Jean-Michel Molina, Hernando Knobel, Philippe Morlat, Abdel Babiker, Anton Pozniac, Francois Raffi, Jose R Arribas

PloS one 2019;14(1):e0209911

Free Full Text

Abstract

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).

Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, Martina Toby, Christine Mant, John Cason, Keith Burling, Emily Wandolo, Isabelle Jendrulek, Chris Taylor, Fowzia Ibrahim, Ranjababu Kulasegaram, Alastair Teague, Frank A Post, Julie Fox

Antiviral therapy 2018;21(4):287-96

Full Text

Abstract

Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.

Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Marco Borderi, Matteo Conti, Rita Mancini, Pierluigi Viale

Antiviral therapy 2018;21(3):217-24

Full Text

Abstract

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

Jhon Rojas, Jose L Blanco, Sonsoles Sanchez-Palomino, Maria A Marcos, Alberto C Guardo, Ana Gonzalez-Cordon, Montserrat Lonca, Amparo Tricas, Ana Rodriguez, Anabel Romero, Jose M Miro, Josep Mallolas, Jose M Gatell, Montserrat Plana, Esteban Martinez

AIDS (London, England) 2019;32(12):1633-1641

Full Text

Abstract

A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet.

Jennifer King, Matthew McCall, Anthony Cannella, Michael Anne Markiewicz, Amanda James, Chantelle B Hood, Edward P Acosta

Journal of acquired immune deficiency syndromes (1999) 2011;56(5):e130-2

Full Text

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.

Purificación Cid-Silva, Noelia Fernández-Bargiela, Luis Margusino-Framiñán, Vanesa Balboa-Barreiro, Álvaro Mena-De-Cea, Soledad López-Calvo, Pilar Vázquez-Rodríguez, Isabel Martín-Herranz, Enrique Míguez-Rey, Eva Poveda, Ángeles Castro-Iglesias

Basic & clinical pharmacology & toxicology 2019;124(4):479-490

Free Full Text

Abstract

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Magda Opsomer, Kimberley Brown, Romana Petrovic, Joseph J Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A Post, Stéphane De Wit, John Jezorwski

Antiviral research 2020;170():104543

Free Full Text

Abstract

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Michael Miller, Hedy Teppler, Peter Sklar, Edwin DeJesus, Bach-Yen Nguyen, Michael S Saag, Yazdan Yazdanpanah, Mark J DiNubile, Hong Wan, Jeffrey L Lennox, Anthony J Rodgers, Randi Leavitt, Monica L Walker, Jürgen K Rockstroh

Journal of acquired immune deficiency syndromes (1999) 2013;63(1):77-85

Full Text

Abstract

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

E Dejesus, A Mills, L Bhatti, C Conner, S Storfer

International journal of clinical practice 2012;65(12):1240-9

Full Text

Abstract

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

Georg Behrens, Renato Maserati, Armin Rieger, Pere Domingo, Florian Abel, Hui Wang, Gill Pearce

Antiviral therapy 2013;17(6):1011-20

Full Text

Abstract

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.

Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Aurora Borioni, Simona Coladonato, Bianca Granozzi, Pierluigi Viale

Infectious diseases (London, England) 2020;52(4):249-256

Full Text

Abstract

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Samir K Gupta, Deming Mi, Sharon M Moe, Michael P Dubé, Ziyue Liu

Journal of acquired immune deficiency syndromes (1999) 2014;64(3):279-83

Free Full Text

Abstract

Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.

Patawee Boontanondha, Hataikarn Nimitphong, Suchawadee Musikarat, Aschara Ragkho, Sasisopin Kiertiburanakul

Current HIV research 2021;18(1):52-62

Free Full Text

Abstract

Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.

William J Hey-Cunningham, John M Murray, Ven Natarajan, Janaki Amin, Cecilia L Moore, Sean Emery, David A Cooper, John Zaunders, Anthony D Kelleher, Kersten K Koelsch

AIDS (London, England) 2016;29(8):911-9

Full Text

Abstract

Results: 1 – 15 / 15

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination""[mesh_terms]

Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).

Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet.

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.

Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.

Results for

""Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination""[mesh_terms]